| Developing cohort | Validation cohort | ||
---|---|---|---|---|
HR (95% CI) | P | HR (95% CI) | P | |
TNM stage |  | < 0.001 |  | < 0.001 |
 II vs. I | 3.781 (2.844–5.025) | < 0.001 | 3.580 (2.481–5.165) | < 0.001 |
 III vs. I | 7.476 (5.481–10.20) | < 0.001 | 5.928 (3.968–8.857) | < 0.001 |
G-ki67 |  | < 0.001 |  | < 0.001 |
 II vs. I | 1.299 (1.038–1.624) | 0.022 | 1.374(1.011–1.867) | 0.042 |
 III vs. I | 1.942 (1.477–2.554) | < 0.001 | 2.756 (1.920–3.956) | < 0.001 |
Adjuvant therapy, without vs. with | 2.788 (2.275–3.416) | < 0.001 | 2.232 (1.703–2.924) | < 0.001 |